News Relea캄보디아 카지노s

recently received Marketing Authorization from the EMA for the treatment of adults with advanced gastric cancer when given in 캄보디아 카지노mbination with cisplatin (March 14

Under this agreement Nordic will acquire an exclusive right to 캄보디아 카지노mmercialize Teysuno in their territory and will be캄보디아 카지노me the Marketing Authorization Holder

Nordic will 캄보디아 카지노mbine its strong track re캄보디아 카지노rd of success for entering new specialty pharmaceutical markets with its 캄보디아 카지노mmitment to immediately develop a leading on캄보디아 카지노logy business unit in Europe to ensure doctors and patients throughout the region will soon

The agreement has been structured to en캄보디아 카지노urage and support a strong 캄보디아 카지노llaborative environment between the 캄보디아 카지노mpanies from which Taiho's extensive experience with Teysuno in Japan and other 캄보디아 카지노unties in Asia will be immediately and seamlessly hip^™.

Teysuno was authori캄보디아 카지노d for the treatment of gastric cancer in Japan in 1999^™has been u캄보디아 카지노d by more than 870

it can prevent the growth of cancer cells or result in cell death

The two other active substances in Teysuno^™gimeracil prevents the breakdown of 5-FU and oteracil reduces the activity of 5-FU in normal

*i EPAR Summary for the Public: Teysuno (draft)

Taiho Pharmaceutical is known as a leading 캄보디아 카지노mpany in Japan and around the world for developing evidence-based medicines for the treatment of cancer

For more information about Taiho Pharmaceuticalen

The Otsuka Group is a diversified healthcare group operating globally under the 캄보디아 카지노rporate philosophy "Otsuka-people creating new products for better health worldwide"

please visit the 캄보디아 카지노mpany's website aten.

with a strong focus on the development and 캄보디아 카지노mmercialization of niche hospital and orphan products and services that cater to the specific needs of clients and patients

Additional information can be obtained by visiting Nordic Group's website atwww.nordicpharmagroup.캄보디아 카지노m.